MetaCap

GT Biopharma Inc. (GTBP)

NASDAQ: GTBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.96-0.22 (-6.92%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GTBP stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$128.61
52-week range
2.87 – 23.60
Day range
2.87 – 3.20
Volume / Avg
39.69K / 78.16K
Beta
—

52-week range

$2.87$23.60

GTBP stock today

Shares of GT Biopharma (GTBP) finished lower on Nov 20 at $2.96, a drop of 6.92% or $0.22 per share, versus the S&P 500's 3.70% decline. Shares are 87.5% below their 52-week high of $23.60 and 3.2% above the 52-week low of $2.87, near the bottom of the past year's range. GTBP is up 277.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 303.3%.

GT Biopharma has posted a net loss over the last twelve months (EPS of -$128.61), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About GT Biopharma

Company profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Michael Martin Breen L.L.B.
Headquarters
San Francisco, CA
Employees
1

Financial highlights

Full financials

GT Biopharma reported a net loss of $28.4 million, compared with a loss of $13.2 million a year earlier. Diluted earnings per share came in at -$6.68.

GT Biopharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-28.35M$-13.16M$-7.60M$-20.88M$-58.01M
EPS (diluted)$-6.68$-6.94$-5.64$-19.66$-2.06

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$75.00+2433.78%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-1.98 vs —

GTBP news

All GTBP news

GT Biopharma peers

Health Care sector
GTBP peer companies
CompanyPrice% ChgMarket capCompare
KYNBKyntra Bio Inc.1.56-13.33%$6.32Mvs GTBP
FBLGFibroBiologics Inc.0.705-15.06%$6.34Mvs GTBP
ACXPAcurx Pharmaceuticals Inc.1.04+0.97%$6.30Mvs GTBP
ADXNAddex Therapeutics Ltd ADR3.47+2.06%$6.08Mvs GTBP
ENVBEnveric Biosciences Inc.1.35-4.26%$6.04Mvs GTBP
BFRGBullfrog AI Holdings Inc.0.3556-8.84%$6.65Mvs GTBP
XCURExicure Inc.0.9001-12.82%$5.89Mvs GTBP
MTVAMetaVia Inc.1.01-7.34%$6.81Mvs GTBP

Indexes, lists and sector

GT Biopharma stock FAQ

What is GT Biopharma's stock price today?

GTBP last traded at $2.96 as of Nov 20, 4:00 PM EST, down 6.92% on the day. Prices are delayed at least 15 minutes.

Does GT Biopharma pay a dividend?

No. GT Biopharma does not currently pay a regular cash dividend.

Who is GT Biopharma's CEO?

Mr. Michael Martin Breen L.L.B. is the chief executive officer of GT Biopharma Inc., which has about 1 employees.

Has GTBP ever split its stock?

Yes. The most recent GTBP stock split was a 1-for-25 split on Sep 8, 2026, one of 3 splits on record.

What is the GTBP 52-week high?

The 52-week high for GTBP is $23.60 and the 52-week low is $2.87. The stock is currently 87.5% below its high.

Compare GTBP